Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441889 · ClinicalTrials.gov registry record · Phase 1
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
A Phase 1 study, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT07441889 is a Phase 1 study that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 23 participants.
The verdict
NCT07441889, a Phase 1 study, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.
Interventions
- DRUG HER2 FPBMC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-06 |
| Est. Completion | 2032-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441889
The ClinicalTrials.gov registry entry for NCT07441889 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HER2 FPBMC is the first listed.
NCT07441889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07441889 about?
NCT07441889 is a clinical study titled "HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)". The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC b...
What is the current status of trial NCT07441889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2026-06. Estimated completion is 2032-10.
What interventions are being tested in trial NCT07441889?
The interventions under investigation include: HER2 FPBMC (DRUG).
Who is sponsoring clinical trial NCT07441889?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.